A second-sign prospective restriction of select broad-spectrum antimicrobials was fully implemented in January 2015 as a pediatric antimicrobial stewardship program (ASP) initiative to help ensure the most appropriate empiric use of ceftaroline, cefepime, fidaxomicin, linezolid, and vancomycin (intravenous). The objective of this evaluation is to assess the effectiveness of a forced second-sign process in the electronic medical record as a pediatric ASP strategy. We anticipated that the second-sign process for antibiotics would increase the appropriateness of empiric antibiotic use, as defined by preapproved criteria, clinical pathways, national guidelines, and pediatric-specific infectious diseases reference texts, while not causing significant delay in the initial administration of antibiotic therapy.
The Infectious Diseases Society of America (IDSA) published guidelines in 2007 and 2016 that highlighted the importance of antimicrobial stewardship programs (ASPs) in both adult and pediatric patient populations [1, 2] . These guidelines recommend the use of preauthorization and/or prospective audit and feedback as core components of ASP activities. Guideline recommendations for ASPs are based on evidence-based literature. The literature specific to the pediatric institutions has shown that ASPs are effective at optimizing antimicrobial use, decreasing unnecessary antimicrobial use, and decreasing the emergence of antimicrobial resistance [3] [4] [5] [6] . Although the benefit of ASP initiatives is clear, strategic approaches to ASP efforts differ across institutions, and outcomes may be based on the strategic approach that is used [4] [5] [6] .
At Connecticut Children's Medical Center, a 187 beds freestanding teaching children's hospital, there are currently various ASP strategies (both prospective and retrospective) to guide the appropriate use of antimicrobial agents. Among these are the development of institution-specific clinical treatment guidelines, provider education, and the audit and review of positive microbiology results and new (within 24-72 hours) antimicrobial orders that are performed Monday through Friday by an Infectious Diseases (ID) pharmacist. In addition, certain antimicrobials are restricted and require ID approval for use. Historically, the antimicrobial restriction process allowed antibiotics to be ordered and followed up by ID and pharmacy. This was then changed to a computerized pilot that required prescribers to indicate during restricted antibiotic order entry that they had obtained ID approval for use. This additional prompting improved prescribing, but it was noticed that many antibiotics were still not being prescribed appropriately. Therefore, upon moving to an electronic medical record (EMR) system, we worked with the EMR to create a second-sign prospective restriction process. In addition to meeting with the EMR build teams, appropriate education was provided to the providers and pharmacists before implementation and continually as needed. The process was fully implemented in January 2015 as an ASP initiative to help ensure the most appropriate empiric use of ceftaroline, cefepime, fidaxomicin, linezolid, and vancomycin (intravenous [IV] only).
This second-sign restriction at our institution is a forced function in the EMR that requires either an ID physician or a pharmacist to provide a second signature for the order to become active. Each of the second-sign restricted antibiotics is only available for ordering in the EMR as a "second-sign" order. Specifically, 2 separate orders are created within the restricted antimicrobial order. The first order is for 18 hours and the second order is for continuation of therapy, after the completion of the initial 18-hour order. In addition to the order being noted as being a second-sign, there is a message in the order to page the ID physician during normal business hours. Once signed by the ordering prescriber, the order does not become active until an ID physician or pharmacist approves the order and provides a second signature.
At all hours, staff pharmacists approve (ie, activate) and verify orders for patients whose condition or location are preapproved by the ASP committee. Currently, only vancomycin has preapproved criteria for use, which allows for use in the pediatric intensive care unit (PICU), neonatal intensive care unit (NICU), emergency department (ED), as well as for patients in any location with septic shock, meningitis, febrile neutropenia, or perioperatively (up to 24 hours for this indication). Preapproved criteria are determined by the indication that the prescriber indicates upon ordering the medication.
For all non-preapproved criteria, the approval process depends upon whether the antibiotic is ordered within normal business hours. During normal business hours (Monday through Friday, 8:30 am-4:30 pm), orders must be reviewed and approved by ID. Outside of normal business hours, staff pharmacists are authorized to approve and verify the initial 18-hour medication order, but continued use requires subsequent cosignature by ID.
The objective of this evaluation is to assess this second-sign process and its effectiveness as an ASP strategy. We hypothesize that the use of the second-sign process would increase the appropriateness of empiric antibiotic use (according to institution-specific pathway recommendations and national standards of patient care), while not causing significant delay in the initial administration of antibiotic therapy.
METHODS
A before and after retrospective, observational study of all patients admitted who were treated with ceftaroline, cefepime, fidaxomicin, linezolid, or IV vancomycin between July 1, 2014 and June 30, 2015 was conducted to evaluate the implementation of a second-sign ASP process. Exclusion criteria included (1) a medication order for the continuation of previously approved therapy or (2) whether the medication was never administered.
Appropriateness of antibiotic use was determined based upon review of the EMR to determine the patient's condition being treated. Appropriate use was defined as either empiric use for preapproved criteria or any use that was in accordance with treatment standards set forth by national treatment guidelines (eg, IDSA, American Academy of Pediatrics [AAP], American Heart Association), hospital-specific clinical pathways, AAP RedBook, or other evidence-based literature. Specifically, in cases when the therapy was not per preapproved criteria, national guidelines, or AAP Redbook, a literature search was performed to determine whether therapy was reasonable. Patient history that was significant for medication allergies and/ or drug-associated adverse effects was also considered when determining antibiotic appropriateness. For example, the use of linezolid instead of vancomycin was deemed appropriate for patients with a history of vancomycin-associated acute kidney injury.
In addition to the appropriateness of antibiotic use, an analysis was conducted to ensure that the process did not result in a significant delay of medication to the patient. Time to medication administration was calculated as the difference, in minutes, between time of initial order entry and the administration time charted by the bedside nurse on the electronic medication administration record. Time to order verification and administration were not collected for IV vancomycin orders given in the ED or intraoperatively, because they are automatically verified through the EMR and are dispensed from automated dispensing cabinets. Likewise, if medication orders were retimed by nursing staff, they were not included in time to administration calculations.
Medication orders were divided into 2 cohorts, "before" or "after" second-sign implementation, based on whether they were entered in the 6 months before or after the second-sign go-live date. Collected patient demographics and clinical information included the following: age, sex, admitting diagnosis, history of relevant multidrug-resistant organisms within the past 12 months, indication for second-sign antibiotic, location of medication order (ie, PICU, NICU, medical/surgical floor, ED), second-sign authorizer, and formal ID consult. Collected clinical laboratory data were reflective of the nearest time point to the restricted antibiotic medication order and was used to interpret clinical appropriateness of antibiotics.
Statistical Analysis
The proportion of patients with appropriate empiric use of second-sign restricted antibiotics and the percentage of preapproved conditions for restricted antibiotic use were compared between the "before" and "after" second-sign groups using χ tests. The time to initial order verification, time to second-sign approval, and time from order verification to medication administration were compared between groups using MannWhitney U tests.
RESULTS
A total of 1178 medication orders for second-sign restricted antibiotics were identified. Orders were excluded if they were a continuation of a previously approved order (n = 763) or were not administered (n = 26) ( Figure 1) . A total of 389 orders were included. The median patient age was 6 years (interquartile range [IQR], 1-13), and 60.9% were male. The most commonly ordered second-sign medication in both groups was vancomycin (92%), followed by linezolid (6%) and cefepime (1.8%). There were no medication orders for ceftaroline or fidaxomicin.
Because vancomycin was the predominant medication prescribed, it was the only group in which differences were specifically evaluated. Differences between indication for use differed only for febrile neutropenia, which was more common in the before group (Table 1) . Overall, categories of bone, joint, or skin infections (15.5% vs 17%) and bacteremia/sepsis (21.9% vs 26.5%) were among the most common indications for antimicrobial use.
The appropriateness was 84.5% (185 of 219) among all medication orders in the before group and 92.9% (158 of 170) in the after group (P = .01). The appropriateness of all second-sign restricted antibiotics and vancomycin specifically is reported in Table 2 and Table 3 , respectively. Of all medication orders evaluated (before and after), 58% (227 of 389) met criteria based on either location or indication (49% [192 of 389] location and 26.2% [102 of 389] indication; some met both criteria). There were no differences in percentage of medication orders that were preapproved by location (46.1% vs 53.5%, P = .147), indication (29.7% vs 21.8%, P = .078), or for either reason (58.0% vs 58.8%, P = .869) between the before and after groups. For the patients receiving vancomycin outside of the critical care units (location appropriate), appropriate uses of vancomycin included the following: culture-proven infection based on susceptibility, meningitis, worsening of infections while receiving otherwise appropriate therapy (eg, orbital cellulitis, osteomyelitis), susceptibility to and/or patient history of central line infection, febrile neutropenia, and pathway-based skin and soft tissue infection, which incorporates patient history, severity, or susceptibility, and perioperative with allergy to β-lactams. Common inappropriate uses were fever, community-associated intra-abdominal infection (eg, appendicitis), usage for skin and soft tissue infections that was not based on pathway recommendations or susceptibility, nonsevere nonpathway-based community-acquired pneumonia usage and central line infections where susceptibility did not support the usage of vancomycin. For the other antibiotic medication orders not meeting preapproved location or indication criteria, appropriate indications for second-sign antibiotics included the following: culture-directed therapy based on sensitivity results, history of patient allergy to first-line preferred antibiotic therapy, the use of linezolid in patients with a history of vancomycin-associated acute kidney injury. In the after group, 11.8% (20 of 170) of all orders were initially approved by ID during normal business hours. Ninetyeight orders were approved by pharmacists due to preapproved criteria. Another 52 orders did not meet preapproval requirements but were granted initial off-hour pharmacist approval for subsequent follow-up evaluation by ID. Of these 52 orders approved off hours, only 20 (38.5%) were continued by ID.
As previously discussed and illustrated by Figure 1 , time from initial order entry to medication administration was not collected for 60 vancomycin orders in the ED (28 before, 32 after), and 21 medication orders were retimed by nursing staff (13 before, 8 after). The addition of the second-sign approval step to the medication ordering process raised concern for potential delays in antibiotic administration and patient care. However, this was not the case, as is shown in Table 4 . The median time from initial order entry to medication administration was 184.5 (IQR, 110.25-280.75) minutes in the before group and 174 (IQR, 104-228) minutes in the after group, which was not statistically significant (P = .342).
DISCUSSION
Quality assessment of ASPs is important. There are published data evaluating the effects of pediatric ASPs on antibiotic use, antibiotic cost, and patient safety, but studies focusing on ASP effects on clinical outcomes and antimicrobial appropriateness are needed [7] . To the best of our knowledge, ours is the first study to evaluate the effects of a second-sign forced EMR preauthorization function on antibiotic appropriateness in a children's hospital. The results of this evaluation suggest that this process can lead to increased appropriateness of restricted antibiotic use, without causing a delay in antibiotic administration. The inclusion of preapproved criteria for antibiotic use and the approval of an initial 18-hour order during off-hours are important mechanisms that facilitate the second-sign process.
Although the improvement in appropriateness of antibiotic usage is very important, the fact that we did not see any increase in the time to antibiotic administration is paramount. With the additional steps required for order approval by the second-sign restriction process, we wanted to ensure that timeliness of patient care was not hindered. In reviewing the second-sign process, we believe that allowing staff pharmacists to approve second-sign orders for preapproved indications and during off-hours is helpful. Their daily workflow requires frequent computer use, and they are often the first to identify a newly entered second-sign order. Subsequently, they are then able to either approve the second-sign order directly (when preapproved criteria exist) or notify a member of the ID team (ID attending, ID pharmacist, or ID pharmacy resident) of orders awaiting approval.
The high percentage of vancomycin second-sign antibiotic orders at our institution is not surprising, because the use of other second-sign restricted antibiotics has been mitigated through other ASP efforts, such as provider education and institution-specific treatment pathways. For example, the emergence of a locally described efflux pump and subsequent dramatic increase in Pseudomonas aeruginosa resistance to cefepime in recent years led to promotion of ceftazidime or piperacillin/ tazobactam as preferred, first-line antipseudomonal agents [8] .
In pediatrics, other studies have evaluated the effects of various ASP processes on antibiotic prescribing patterns, but none specific to a second-sign process [9] [10] [11] [12] . Data suggest that although prospective audit and feedback may be helpful, it alone is likely not enough. Specifically, one pediatric study evaluating audit and feedback stewardship methods for vancomycin and cefepime reported that only 11.4% (35 of 308) and 6.0% (13 of 215) of antibiotic courses, respectively, were deemed appropriate by 2 ID reviewers [9] . Such a low percentage of appropriate use with audit and feedback suggests that the addition of antimicrobial restriction and preauthorization are needed. Preauthorization is recommended as a core component of ASP programs, and its successful implementation is important to ASP success [1, 2] . One study evaluated the effect of a paper antibiotic ordering form on the appropriateness of vancomycin (IV or oral) use at a 325-bed tertiary care, teaching children's hospital [10] . Overall, compliance with the paper form was poor; however, even when compliance improved, the inappropriateness of vancomycin use actually worsened (35% to 51% before and after implementation [P < .01]) [10] . More importantly, the use of a paper antibiotic order form in this study relied on provider compliance and did not force restricted antibiotic order review for approval. This study highlights some potential pitfalls of relying solely on a paper antibiotic order form or indication selection in the EMR as voluntary processes for ordering restricted agents.
Automated technologies are powerful tools that can be used to optimize preauthorization strategies and encourage appropriate empiric antibiotic regimens. The incorporation of these technologies into the prior-authorization ASP process has led to improvements in antibiotic usage in both the adults and pediatrics [11, 13] . A multi-intervention approach to treatment of community-acquired pneumonia in adult patients increased the appropriateness of empiric antibiotic selection (54.9% to 93.4% [P < .001] and 64.6% to 91.3% [P = .004]) at an urban, multicampus academic medical center by using both a treatment algorithm and automated antibiotic dispensing to guide appropriate antimicrobial selection [13] . Another study evaluated the impact of electronic preauthorization for restricted antibiotics in a children's hospital in Japan. The authors reported that an electronic block of specific antipseudomonal antibiotics outside of the PICU or NICU resulted in a decrease in carbapenem, piperacillin/tazobactam, and ceftazidime usage per 1000 patient days, without any significant increases in other antipseudomonal antibiotic use [11] . Although the study demonstrated a decrease in antibiotic exposures, it did not evaluate appropriateness and was unable to show any difference in P. aeruginosa susceptibilities, all-cause mortality, or 30-day mortality.
The use of antimicrobial restriction requiring preauthorization in addition to prospective review and feedback appears to have the best likelihood of success in an ASP. The addition of a preauthorization process to the prospective audit and feedback of 1 ASP at a children's hospital reduced IV vancomycin use by an additional 16% overall [12] . It is important to note that, similar to our study, these results showed that preauthorization led to a decrease in the overall usage of vancomycin. However, the authors did not assess the impact of preauthorization on appropriateness of vancomycin use. Although overall antibiotic use is important, it is also important to be able to show that the usage is well targeted. Our second-sign evaluation shows the impact of such an intervention on the improvement of antibiotic use in a children's hospital, especially for vancomycin.
There are several limitations to our second-sign evaluation. First, this was a retrospective chart review at a single children's hospital evaluating a year of medication orders for a limited number of antibiotics (ie, largely vancomycin). There are also controversies regarding what determines appropriate use of antibiotics, especially in pediatrics. We tried to account for this by using our preapproved criteria and institution-specific clinical pathways, we reviewed national treatment guidelines and the AAP Redbook to determine whether the usage fell within standards of care. Data collection and interpretation were further limited by an inability to effectively capture medication orders that were rejected by ID during normal business hours, because they never became an active order. The significant decrease in the number of second-sign orders occurred at the same time there was an increase in appropriate antibiotic use (between the before and after second-sign groups). This decrease occurred at the same time as we observed a high percentage of initial 18-hour orders not approved by ID. This leads us to believe that the second-sign medication restriction likely prevented many orders during the day from even being started. In addition, this process was not implemented without issue. It required significant initial and continued education of all medical and pharmacy staff as well as significant additional effort for ID and pharmacy with continued process expansion. These data show that second-sign is an effective method for restricted antimicrobial preauthorization that can be added to prospective audit and feedback efforts to further improve appropriateness of antibiotics in children.
CONCLUSIONS
The results of this study suggest that the use of a second-sign restriction process for restricted antimicrobials that is added to prospective audit and feedback can lead to an increase in appropriate antimicrobial use. Furthermore, the addition of this process did not result in a delay of antibiotic administration to the patient. More studies are needed to confirm these results at other pediatric hospitals and with additional antimicrobials.
